Development and external validation of the Munich Sorafenib Evaluation Score for hepatocellular carcinoma

Introduction: In recent years increasing options for systemic HCC treatment have become available. The development of therapy-specific prognostic scores has been encouraged. Tailoring therapy to individual patients requires prognostic scores for treatment success in addition to the Barcelona-Clinic-Liver-Cancer (BCLC) classification. We have developed and validated a prognostic score for patients treated with sorafenib. Methods: Prognostic factors identified in a multivariate analysis of 108 sorafenib patients were used to construct the Munich-Sorafenib-Evaluation score (M-SE). M-SE and 9 established HCC prognostic systems were ranked according to concordance-index and AIC. External M-SE-validation was performed in an independent HCC sorafenib cohort (n=101) derived from the prospective multicentre randomized controlled SORAMIC trial. Results: Ascites (p
Source: Digestive Diseases - Category: Gastroenterology Source Type: research